Product Description
Plecanatide is used in adults to treat chronic idiopathic constipation (CIC; difficult or infrequent passage of stools that lasts for 3 months or longer and is not caused by a disease or a medication) and irritable bowel syndrome with constipation (IBS-C; a condition that causes stomach pain or cramps, bloating, and constipation.) Plecanatide is in a class of medications called guanylate cyclase-C agonists. It works by increasing the movement of food and waste through the stomach and intestines. (Sourced from: https://medlineplus.gov/druginfo/meds/a617020.html)
Mechanisms of Action: GUC Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | United States
Approved Indications: Irritable Bowel Syndrome | Constipation
Known Adverse Events: Diarrhea
Company: Bausch Health Americas
Company Location: QUEBEC A8 H7L 4A8
Company CEO: Thomas J. Appio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Constipation
Phase 2: Irritable Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| (IBS-C) | P2 |
Recruiting |
Constipation|Irritable Bowel Syndrome |
2023-12-01 |
24% |
| NC011901 | P3 |
Completed |
Constipation |
2023-10-12 |
|
| CTR20210927 | P3 |
Not yet recruiting |
Constipation |
None |